Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 12 (December)

1. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
   Nat Clin Pract Oncol, 3(12): 682-92. [Abstract] [Full-text]
2. How many drug targets are there?
   Nat Rev Drug Discov, 5(12): 993-6. [Abstract] [Full-text]
3. Breast cancer risk in postmenopausal women using estrogen-only therapy.
   Obstet Gynecol, 108(6): 1354-60. [Abstract] [Full-text]
4. Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies.
   J Surg Oncol, 94(8): 725-36. [Abstract] [Full-text]
5. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
   J Surg Oncol, 94(7): 599-606. [Abstract] [Full-text]
6. Brain cancer diagnosis and therapy with nanoplatforms.
   Adv Drug Deliv Rev, 58(14): 1556-77. [Abstract] [Full-text]
7. Multifunctional nanocarriers.
   Adv Drug Deliv Rev, 58(14): 1532-55. [Abstract] [Full-text]
8. Nanomedicine: developing smarter therapeutic and diagnostic modalities.
   Adv Drug Deliv Rev, 58(14): 1456-9. [Abstract] [Full-text]
9. Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
   Gynecol Oncol, 103(3): 783-92. [Abstract] [Full-text]
10. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.
    Gynecol Oncol, 103(3): 1038-42. [Abstract] [Full-text]
11. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences.
    Gynecol Oncol, 103(3): 1105-8. [Abstract] [Full-text]
12. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles.
    Eur J Pharm Biopharm, 65(1): 10-7. [Abstract] [Full-text]
13. Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system.
    Eur J Pharm Biopharm, 65(1): 94-8. [Abstract] [Full-text]
14. Development of a biodegradable alginate carrier system for antibiotics and bone cells.
    J Orthop Res, 25(1): 62-72. [Abstract] [Full-text]
15. In vitro erythemal UV-A protection factors of inorganic sunscreens distributed in aqueous media using carnauba wax-decyl oleate nanoparticles.
    Eur J Pharm Biopharm, 65(1): 122-5. [Abstract] [Full-text]
16. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery.
    Eur J Pharm Biopharm, 65(1): 85-93. [Abstract] [Full-text]
17. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models.
    Eur J Pharm Biopharm, 65(1): 68-77. [Abstract] [Full-text]
18. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers.
    Eur J Pharm Biopharm, 65(1): 26-38. [Abstract] [Full-text]
19. Solid lipid microparticles as a sustained release system for pulmonary drug delivery.
    Eur J Pharm Biopharm, 65(1): 47-56. [Abstract] [Full-text]
20. Novel composite fiber structures to provide drug/protein delivery for medical implants and tissue regeneration.
    Acta Biomater, 3(1): 51-7. [Abstract] [Full-text]
21. Development and characterization of film forming polymeric solutions for skin drug delivery.
    Eur J Pharm Biopharm, 65(1): 111-21. [Abstract] [Full-text]
22. Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery.
    Eur J Pharm Biopharm, 65(1): 39-46. [Abstract] [Full-text]
23. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations.
    Eur J Pharm Biopharm, 65(1): 78-84. [Abstract] [Full-text]
24. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats.
    Int J Cancer, 120(2): 420-31. [Abstract] [Full-text]
25. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer.
    Semin Oncol, 33(6): 664-71. [Abstract] [Full-text]
26. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.
    Am J Med, 119(12): 1056-61. [Abstract] [Full-text]
27. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Int J Cancer, 120(3): 605-10. [Abstract] [Full-text]
28. Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
    Am J Clin Oncol, 29(6): 576-82. [Abstract] [Full-text]
29. A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
    Am J Clin Oncol, 29(6): 555-61. [Abstract] [Full-text]
30. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.
    JAMA, 296(21): 2563-71. [Abstract] [Full-text]
31. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.
    Blood, 108(13): 3997-4002. [Abstract] [Full-text]
32. Micellar nanocarriers: pharmaceutical perspectives.
    Pharm Res, 24(1): 1-16. [Abstract] [Full-text]
33. Disruption of epithelial tight junctions by yeast enhances the paracellular delivery of a model protein.
    Pharm Res, 24(1): 37-47. [Abstract] [Full-text]
34. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.
    Expert Opin Biol Ther, 7(1): 31-40. [Abstract] [Full-text]
35. Insulin infusion therapy for myocardial infarction.
    Expert Opin Pharmacother, 7(18): 2495-503. [Abstract] [Full-text]
36. Kidney cancer therapy: new perspectives and avenues.
    Expert Opin Pharmacother, 7(18): 2481-93. [Abstract] [Full-text]
37. Current breast cancer risks of hormone replacement therapy in postmenopausal women.
    Expert Opin Pharmacother, 7(18): 2455-63. [Abstract] [Full-text]
38. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis.
    Am J Surg, 192(6): 782-8. [Abstract] [Full-text]
39. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
    BMC Cancer, 6: 274. [Abstract] [Full-text]
40. The International Classification of Retinoblastoma predicts chemoreduction success.
    Ophthalmology, 113(12): 2276-80. [Abstract] [Full-text]
41. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
    Ophthalmology, 113(12): 2243-50. [Abstract] [Full-text]
42. Vitamin E but not St. John's wort mitigates leukopenia caused by cancer chemotherapy in rats.
    Transl Res, 148(6): 315-24. [Abstract] [Full-text]
43. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent.
    Am Heart J, 152(6): 1168-74. [Abstract] [Full-text]
44. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry.
    Am Heart J, 152(6): 1146-52. [Abstract] [Full-text]
45. Comparison of sirolimus-eluting and bare metal stents in coronary bifurcation lesions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease Trial (SCANDSTENT).
    Am Heart J, 152(6): 1140-5. [Abstract] [Full-text]
46. Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center.
    Am Heart J, 152(6): 1007-14. [Abstract] [Full-text]
47. New frontiers in the treatment of multiple myeloma.
    ScientificWorldJournal, 6: 1475-503. [Abstract] [Full-text]
48. Seizures during stroke thrombolysis heralding dramatic neurologic recovery.
    Neurology, 67(11): 2048-9. [Abstract] [Full-text]
49. Potentially unintended discontinuation of long-term medication use after elective surgical procedures.
    Arch Intern Med, 166(22): 2525-31. [Abstract] [Full-text]
50. Systemic chemotherapy for advanced bladder cancer: update and controversies.
    J Clin Oncol, 24(35): 5545-51. [Abstract] [Full-text]
51. Chemotherapy for advanced germ cell tumors.
    J Clin Oncol, 24(35): 5493-502. [Abstract] [Full-text]
52. Recurrent bullous retinal detachments from photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.
    Am J Ophthalmol, 142(6): 1079-81. [Abstract] [Full-text]
53. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.
    Am J Ophthalmol, 142(6): 1072-4. [Abstract] [Full-text]
54. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    J Urol, 177(1): 84-9; discussion 89. [Abstract] [Full-text]
55. Nitrous oxide for monitoring fluid absorption in volunteers.
    Br J Anaesth, 98(1): 53-9. [Abstract] [Full-text]
56. Predictive performance of 'Servin's formula' during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients.
    Br J Anaesth, 98(1): 66-75. [Abstract] [Full-text]
57. Management of failed thrombolysis after acute myocardial infarction: an overview of current treatment options.
    Int J Cardiol, 114(3): 291-9. [Abstract] [Full-text]
58. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance.
    Eur J Vasc Endovasc Surg, 33(1): 116-21. [Abstract] [Full-text]
59. Flow-related techniques for preoperative goal-directed fluid optimization.
    Br J Anaesth, 98(1): 38-44. [Abstract] [Full-text]
60. In-stent restenosis in idiopathic isolated ostial left main coronary artery stenosis.
    Int J Cardiol, 114(3): e111-3. [Abstract] [Full-text]
61. Treatment of varicocele with reference to age: a retrospective comparison of three minimally invasive procedures.
    Surg Endosc, 21(1): 61-5. [Abstract] [Full-text]
62. Impaired health status in Type D patients following PCI in the drug-eluting stent era.
    Int J Cardiol, 114(3): 358-65. [Abstract] [Full-text]
63. Intensive extracorporeal photochemotherapy in pediatric patients with chronic graft-versus-host disease (cGVHD).
    Pediatr Blood Cancer, 48(2): 218-21. [Abstract] [Full-text]
64. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
    Pediatr Blood Cancer, 48(2): 132-9. [Abstract] [Full-text]
65. Prescription medications: beliefs, experiences, behavior, and adherence of sheltered housing residents.
    Ann Pharmacother, 40(12): 2123-9. [Abstract] [Full-text]
66. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    N Engl J Med, 355(24): 2542-50. [Abstract] [Full-text]
67. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
    Chest, 130(6): 1803-7. [Abstract] [Full-text]
68. A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia.
    Leukemia, 21(1): 72-8. [Abstract] [Full-text]
69. Assessment of American urologists' approach to hormonal management of prostate cancer.
    Urology, 68(6): 1305-7. [Abstract] [Full-text]
70. Surface coatings determine cytotoxicity and irritation potential of quantum dot nanoparticles in epidermal keratinocytes.
    J Invest Dermatol, 127(1): 143-53. [Abstract] [Full-text]
71. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
    Psychother Psychosom, 76(1): 40-6. [Abstract] [Full-text]
72. Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?
    Psychother Psychosom, 76(1): 5-14. [Abstract] [Full-text]
73. Antimicrobial prophylaxis for endocarditis: emotion or science?
    Heart, 93(1): 5-6. [Abstract] [Full-text]
74. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    Lancet, 368(9553): 2125-35. [Abstract] [Full-text]
75. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Clin Infect Dis, 44(2): 295-300. [Abstract] [Full-text]
76. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study.
    Clin Infect Dis, 44(2): 287-94. [Abstract] [Full-text]
77. Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
    Am Heart J, 153(1): 140-6. [Abstract] [Full-text]
78. How best is to discontinue postmenopausal hormone therapy: immediate or tapered?
    Maturitas, 56(1): 78-83. [Abstract] [Full-text]
79. Clinical guidelines for improving compliance with hormone therapy in Latin American women during the menopausal transition and thereafter.
    Maturitas, 56(1): 101-9. [Abstract] [Full-text]
80. Neurophysiologic changes during estrogen augmentation in perimenopausal depression.
    Maturitas, 56(1): 54-60. [Abstract] [Full-text]
81. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study.
    Maturitas, 56(1): 61-8. [Abstract] [Full-text]
82. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms.
    Maturitas, 56(1): 69-77. [Abstract] [Full-text]
83. Attitudes towards the menopause and hormone therapy over the turn of the century.
    Maturitas, 56(1): 12-20. [Abstract] [Full-text]
84. Knowledge of osteoporosis correlated with hormone therapy use and health status.
    Maturitas, 56(1): 21-9. [Abstract] [Full-text]
85. Physicians' views and practices concerning menopausal hormone therapy.
    Maturitas, 56(1): 30-7. [Abstract] [Full-text]
86. Verteporfin therapy for neovascular age-related macular degeneration in Indian eyes.
    Jpn J Ophthalmol, 50(6): 524-8. [Abstract] [Full-text]
87. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
    J Natl Cancer Inst, 98(24): 1806-18. [Abstract] [Full-text]
88. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
    J Clin Oncol, 24(36): 5742-9. [Abstract] [Full-text]
89. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    J Clin Oncol, 24(36): 5735-41. [Abstract] [Full-text]
90. Hormone replacement therapy and survival after colorectal cancer diagnosis.
    J Clin Oncol, 24(36): 5680-6. [Abstract] [Full-text]
91. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.
    J Clin Oncol, 24(36): 5769-79. [Abstract] [Full-text]
92. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    J Clin Oncol, 24(36): 5664-71. [Abstract] [Full-text]
93. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
    J Clin Oncol, 24(36): 5703-10. [Abstract] [Full-text]
94. A spray catheter technique for pleural anesthesia: a novel method for pain control before talc poudrage.
    Anesth Analg, 104(1): 198-200. [Abstract] [Full-text]
95. Six sigma methodology can be used to improve adherence for antibiotic prophylaxis in patients undergoing noncardiac surgery.
    Anesth Analg, 104(1): 140-6. [Abstract] [Full-text]
96. Premedication with gabapentin: the effect on tourniquet pain and quality of intravenous regional anesthesia.
    Anesth Analg, 104(1): 97-101. [Abstract] [Full-text]
97. Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.
    Br J Ophthalmol, 91(1): 100-4. [Abstract] [Full-text]
98. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery.
    N Engl J Med, 355(25): 2640-51. [Abstract] [Full-text]
99. Collagen shields as a drug delivery system for the fourth-generation fluoroquinolones.
    Ophthalmologica, 221(1): 51-6. [Abstract] [Full-text]
100. Preparation and characterization of N-(2-carboxybenzyl)chitosan as a potential pH-sensitive hydrogel for drug delivery.
     Carbohydr Res, 342(1): 87-95. [Abstract] [Full-text]
101. cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib.
     Cancer Chemother Pharmacol, 59(3): 349-60. [Abstract] [Full-text]
102. TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
     Cancer Chemother Pharmacol, 59(3): 413-8. [Abstract] [Full-text]
103. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
     Cancer Chemother Pharmacol, 59(3): 361-7. [Abstract] [Full-text]
104. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
     Cancer Chemother Pharmacol, 59(3): 313-20. [Abstract] [Full-text]
105. Monitoring and imaging the clot during systemic thrombolysis in stroke patients.
     Expert Rev Cardiovasc Ther, 5(1): 91-8. [Abstract] [Full-text]
106. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
     Stroke, 38(1): 85-9. [Abstract] [Full-text]
107. A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump.
     J Pediatr, 150(1): 103-105.e1. [Abstract] [Full-text]
108. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia.
     Am J Ophthalmol, 143(1): 77-82. [Abstract] [Full-text]
109. Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study.
     Am J Ophthalmol, 143(1): 68-76. [Abstract] [Full-text]
110. Targeting of nanoparticles to the clathrin-mediated endocytic pathway.
     Biochem Biophys Res Commun, 353(1): 26-32. [Abstract] [Full-text]
111. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
     Int J Radiat Oncol Biol Phys, 67(1): 19-30. [Abstract] [Full-text]
112. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
     Int J Radiat Oncol Biol Phys, 67(1): 104-9. [Abstract] [Full-text]
113. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
     Int J Radiat Oncol Biol Phys, 67(1): 110-6. [Abstract] [Full-text]
114. Intracellular delivery can be achieved by bombarding cells or tissues with accelerated molecules or bacteria without the need for carrier particles.
     Exp Cell Res, 313(1): 53-64. [Abstract] [Full-text]
115. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
     N Engl J Med, 355(26): 2733-43. [Abstract] [Full-text]
116. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
     J Clin Oncol, 25(1): 110-7. [Abstract] [Full-text]
117. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
     J Clin Oncol, 25(1): 102-9. [Abstract] [Full-text]
118. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
     J Clin Oncol, 25(1): 85-90. [Abstract] [Full-text]
119. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
     Cancer Immunol Immunother, 56(3): 343-57. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.